Companies/US/SPRY

ARS PHARMACEUTICALS, INC.

Income flow

Annual
SPRY 10-K Income StatementPeriod 2025-12-31Source 10-K
Services & other$72MRevenue Under Collaboration Agreements$10MRevenue Under Supply Agreements$2MRevenue$84M-6% Y/YGross profit$79M-11% Y/YCost of revenue$5M

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$12M
  • Revenue Under Collaboration Agreements$10M80.4%
  • Revenue Under Supply Agreements$2M19.6%
By geography
By geography$84M
  • United States$72M85.7%
  • Non-US$12M14.3%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).99.4MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).48.0M

Valuation

Trailing PE 131.9 (2024-12-31)PE trend

Fiscal PE1

PeriodEPSClosePE
2024-12-310.0810.55131.9

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.